Supplement evidence
SAMe
The depression trials, and the mania and interaction signals.
What Its Legal Status Actually Means
Read this before anything below it. Legal to sell is not the same fact as reviewed, verified, or approved.
SAMe is sold in the US as a dietary supplement under DSHEA. The FDA has not approved it for depression, osteoarthritis, liver disease, or any other condition, and no premarket review of its safety or effectiveness applies. There is no prescription SAMe product in the US, though in some other countries SAMe has been available as a prescription medicine — which is part of why much of the older trial literature used intravenous or intramuscular SAMe at doses that do not map onto the oral tablets on a US shelf. Oral SAMe is chemically unstable and depends on enteric coating and salt form (tosylate, butanedisulfonate) for absorption, so the number on the label and the amount that reaches the bloodstream are not the same thing, and no regulator verifies either before sale.
Quoted whole from the 2026-08-18 study harvest. Not summarized, not shortened.
What the Research Shows
4 records from the 2026-08-18 harvest, each checked against PubMed and Europe PMC on that date. How a study was designed, how many people were in it, and who paid for it are printed above what it found, because those three facts decide how much the finding is worth.
Study 1 · 2016
- Systematic review of randomized trials
- 934 participants
- Top-tier journal
- Independently funded
- Preregistered
- Declared conflicts of interest
gold standard95/100Top of the evidence hierarchy, independently funded.
Eight trials involving 934 adults with major depression produced no strong evidence that SAMe beats placebo as a standalone treatment (SMD -0.54, 95% CI -1.54 to 0.46, P=0.29; 142 participants, 2 studies; very low quality evidence) and no evidence it differs from imipramine (SMD -0.04, 95% CI -0.34 to 0.27; 619 participants) or from escitalopram (mean difference 0.12 points, 95% CI -2.75 to 2.99; 129 participants). The one positive signal was SAMe added on top of an SSRI, where a single 73-person study showed a 3.9-point advantage (95% CI 0.87 to 6.93) — low quality evidence from one trial. Two cases of mania or hypomania were recorded among 441 SAMe recipients.
How this record was checked
PubMed record 27727432 fetched via NCBI efetch 2026-08-18; title, all ten authors, journal (Cochrane Database Syst Rev 2016;10(10):CD011286), year, DOI, 8 trials, N=934 adults, and every effect estimate quoted above confirmed from the abstract, which also carries a per-author conflict-of-interest statement (hence conflicts true). PMC full text PMC6457972 read 2026-08-18: "CRG Funding Acknowledgement — The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Common Mental Disorders Group", hence funding INDEPENDENT; the PubMed record's "Update of doi:10.1002/14651858.CD011286" confirms a previously published protocol, hence preregistered true.
Study 2 · 2014
- Randomized trial
- 189 participants
- Reputable journal
- Mixed funding
- Preregistered
strong72/100Well-supported by good-quality research.
Read this first: This is a failed trial, not simply a negative one: escitalopram, a drug with established efficacy, also failed to beat placebo, which means the study lacked assay sensitivity and cannot cleanly rule SAMe out. Two later papers re-analysed subsets of the same dataset and reported positive findings — a single-site subsample (Sarris 2014, J Affect Disord, PMID 24856557, n=144, SAMe superior to placebo) and a male-only subgroup (Sarris 2015, Pharmacopsychiatry, PMID 26011569, significant in 51 men, not in 62 women). Post-hoc subgroups from a failed trial are hypotheses, not results.
189 outpatients with major depressive disorder were randomised for 12 weeks to SAMe (1,600-3,200 mg/day), escitalopram (10-20 mg/day), or placebo. All three arms improved by about 5-6 points on the 17-item Hamilton scale and none separated from any other: response was 36% on SAMe, 34% on escitalopram, and 30% on placebo; remission was 28%, 28%, and 17%. The authors' own conclusion is that the results fail to support an advantage over placebo for SAMe — or, notably, for the standard antidepressant used as the active comparator, which marks this as a failed trial rather than a clean negative. Gastrointestinal effects were the commonest complaint on SAMe (19% stomach discomfort, 20% diarrhoea).
How this record was checked
PubMed record 24500245 fetched via NCBI efetch 2026-08-18; title, authors, journal (J Clin Psychiatry 2014;75(4):370-376), year, DOI, N=189, the 12-week design, response and remission rates, and registration NCT00101452 (hence preregistered true) confirmed from the abstract. PMC full text PMC5360105 read 2026-08-18: "This study was supported by the National Institutes of Health (NIH) and the National Center for Complementary and Alternative Medicine (NCCAM), R01 grant R01AT001638... The sponsors had no further role... SAMe tosylate and matching placebo were supplied by Pharmavite LLC, CA" — public funding with industry in-kind study drug, hence MIXED. No separate financial-disclosure statement was located on that page, so conflicts is recorded false.
Study 3 · 2010
- Randomized trial
- 73 participants
- Top-tier journal
- Funding not established
moderate60/100Reasonable evidence with real limitations.
Read this first: 73 participants across two arms is small enough that a handful of responders moves the result, and the trial has not been independently replicated in the sixteen years since — the Cochrane review, published six years later, still cites it as a single study. No funding statement or disclosure statement was read, so both funding and conflicts are recorded conservatively.
73 people whose depression had not responded to an SRI kept taking it and were randomised to add SAMe (800 mg twice daily) or placebo for six weeks. Response was 36.1% on added SAMe versus 17.6% on added placebo, and remission 25.8% versus 11.7% — a number needed to treat of about one in six for response and one in seven for remission. Dropout for any reason (20.6% versus 29.5%) and for adverse events (5.1% versus 8.8%) did not differ. The authors called the results preliminary and explicitly said they warrant replication; this remains the single positive augmentation trial that the Cochrane review's add-on analysis rests on.
How this record was checked
PubMed record 20595412 fetched via NCBI efetch 2026-08-18; title, all five authors, journal (Am J Psychiatry 2010;167(8):942-948), year, DOI, N=73, the 800 mg twice-daily target dose, the 6-week duration, and the response/remission percentages confirmed from the abstract. Europe PMC core record fetched 2026-08-18 lists one NIH grant (NIMH 5-K23 MH-069629) but no funding statement and no PMC full text; the AJP page was not read, so per the format rule funding is recorded UNKNOWN rather than inferred from the grant linkage, conflicts false, and independence left null (unchecked). No trial registration appears in the record, so preregistered is false.
Study 4 · 2017
- Systematic review of observational studies
- Reputable journal
- No funding reported
- Declared conflicts of interest
moderate63/100Reasonable evidence with real limitations.
Read this first: Two of the authors have direct commercial ties to SAMe: the disclosure statement records that Dr Bottiglieri chaired the advisory board of and holds stock options in Methylation Sciences Inc. and is a scientific advisor to Gnosis S.p.A., and Dr Gerbarg receives royalties from books covering SAMe. The review received no funding, and it reports the mania risk plainly, but it is not written by parties independent of the product. It also pools trials of widely varying quality, dose, and route without a meta-analysis, so "promising but limited" is a judgement rather than an effect size.
A work group of the American Psychiatric Association Council on Research screened 174 records and reviewed 132 studies (115 clinical trials, 17 preclinical) of SAMe across psychiatric and medical conditions, concluding that the evidence for major depressive disorder is "promising but limited" for both monotherapy and augmentation. The review documents that mania and hypomania seen in early SAMe studies is the reason subsequent trials confined themselves to unipolar depression — the clearest statement in the literature of why bipolar disorder is a contraindication.
How this record was checked
PubMed record 28682528 fetched via NCBI efetch 2026-08-18; title, authors, the "as Work Group of the American Psychiatric Association Council on Research" byline, journal (J Clin Psychiatry 2017;78(6):e656-e667), year, DOI, and the 174-record/132-study counts confirmed from the abstract. PMC full text PMC5501081 read 2026-08-18: "Funding/Support: None" (hence funding NONE), a full per-author disclosure section (hence conflicts true) including the Methylation Sciences and Gnosis S.p.A. interests quoted above (hence independent false), and the passage stating that observations of SAMe-induced hypomania or mania in early studies limited subsequent trials to unipolar episodes.
The Risks
Nobody checks this purchase the way a prescription is checked. No prescriber reviews it against the rest of what you take, no pharmacist screens the interaction, and no regulator confirms the dose in the capsule before it is sold. That is why this section sits here at full length rather than as a footnote.
What the paragraph below covers:
- Psychosis and mania
- Drug interactions
- Sleep disruption
- Stomach and gut
The risk that actually changes decisions is mania. SAMe can trigger manic or hypomanic switching, and this is not hypothetical: the Cochrane review recorded two reports of mania or hypomania among 441 participants who received SAMe, and the American Psychiatric Association Council on Research review notes that mania observed in the early studies is precisely why later trials restricted enrolment to unipolar depression and excluded bipolar disorder. Anyone with bipolar disorder, a past manic or hypomanic episode, or a strong family history should not start SAMe without a psychiatrist involved. Beyond that, the profile is mostly gastrointestinal — in the 189-person placebo-controlled trial, 19% on SAMe reported stomach discomfort and 20% diarrhoea — plus anxiety, restlessness, and insomnia, which is why it is usually taken earlier in the day. SAMe has most often been studied as an add-on to an SSRI rather than instead of one, so combining is not itself unusual, but starting it alongside an antidepressant should be a prescriber's decision rather than a solo experiment, and it should be discussed before any procedure or new medication that affects mood or methylation (levodopa in Parkinson's disease is a known interaction area).
What Is Not Known
The boundaries of the section above, in the harvest’s own words. What it excluded, why, and where it looked and found nothing. An absence of evidence is not evidence of absence, and it is not evidence of benefit either.
What Was Left Out, and Why
Quoted from the harvest, where these notes sat above the study list rather than after it. Where a note says “below” it means the studies in the section above.
- Sarris 2014 (J Affect Disord, PMID 24856557) and Sarris 2015 (Pharmacopsychiatry, PMID 26011569) were fetched and verified but are excluded as study records: both are post-hoc re-analyses of subsamples from the same failed trial listed here (Mischoulon 2014, NCT00101452), one reporting a positive result in a single-site subsample and one a male-only subgroup effect. Reporting them as independent findings would triple-count one negative trial. Their existence is flagged in that trial's contestedNote.
- The 1970s-80s parenteral (IV/IM) SAMe trials are excluded individually; they are pooled inside the Cochrane review and the APA-affiliated review below, and their dosing does not correspond to the oral tablets sold in US stores.
The Retraction Check
PubMed efetch records for all four PMIDs inspected 2026-08-18 for "Retraction in" flags; none present, and no errata or expressions of concern.
Questions for a Prescriber or Pharmacist
This page does not tell anyone to take SAMe or to avoid it. It is not able to: it does not know what else you take, what you have tried, or what you are treating. These are the questions each study above raises, written to be asked out loud.
- The only place SAMe showed a benefit was added on top of an antidepressant, in one 73-person study — given that, is it worth adding to what I'm taking, and what would you watch for?
- In the largest placebo-controlled SAMe trial, SAMe, escitalopram and placebo all landed in the same place — does that tell us SAMe doesn't work, or that the trial couldn't detect anything?
- If my antidepressant is only partly working, how does adding SAMe compare with the augmentation options you'd normally reach for first?
- Given that SAMe was linked to mania in the early studies, is there anything in my history — or my family's — that would make it a bad idea for me specifically?
And the one to ask at the counter, whatever the answers above turn out to be: given everything I am already taking, what would you want to know about SAMe before I put it in the same body?
Where This Page Comes From
Transcribed from the study-harvest-2026-08-18 record for same, built into this page by scripts/supplement-ingest.mjs on 2026-09-07. Nothing here is fetched at page load, and nothing here was written by a model without a citation behind it.
| Source file | study-harvest/2026-08-18/same.yaml |
|---|---|
| Source repo | REPTechnologies/avalo-backend |
| SHA-256 | 3eca1336ebed9899aff65cc3f90c481332f52d20349497353fb2aa1ac4ac2e90 |
| Also searched as | SAMe, S-adenosyl methionine, S-adenosyl-L-methionine, SAM-e, ademetionine |
The Other Substances
- 5-HTP
- Ashwagandha
- Cannabidiol (CBD)
- Cannabis and THC
- Creatine
- Kratom
- L-Theanine
- Magnesium
- Melatonin
- Methylene Blue
- Microdosing
- N-Acetylcysteine (NAC)
- Omega-3
- Phenibut
- St John’s Wort
- Valerian
Do any supplements actually work? asks the question across all of them. The full library has the medication records, the funding investigations, and the glossary.